This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Relapsed or Refractory Multiple Myeloma
and you are
over 18
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This study will evaluate safety and efficacy of TKI258 in patients with relapsed or refractory multiple myeloma

Provided treatments

  • Drug: TKI258

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01058434. The sponsor of the trial is Novartis Pharmaceuticals and it is looking for 43 volunteers for the current phase.
Official trial title:
A Phase II, Multi-center, Non-randomized, Open-label Study of TKI258 in Patients With Relapsed or Refractory Multiple Myeloma, Who Are With or Without t(4;14) Translocation